Metrics as of 10/13/2026, 06:38 PM (Berlin time), refresh in progress.
Oculis Holding Stock
Oculis Holding AG
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- CEO
- Riad Sherif
- Employees
- 60
- Market cap
- $436 M
- IPO
- 18/05/2021
- Web
- oculis.com
Oculis Holding AG is a biopharmaceutical company in the clinical development stage operating within the biotechnology industry. Headquartered in Zug, Switzerland, the company is led by CEO Riad Sherif and employs 60 employees. The enterprise specializes in the creation of innovative eye drop medications designed to…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Oculis Holding stock: price history
1D
-3.3%
1W
-12.6%
1M
-27.8%
6M
-72.4%
YTD
-61.8%
1Y
-63.7%
2Y
-48.8%
5Y
-22.4%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~23% weaker price swings than usual
Ask the agents about Oculis Holding
Analyst assessment of Oculis Holding
PRICE TARGET LOW
US$26.00
CONSENSUS
US$36.75
MEDIAN
US$38.00
PRICE TARGET HIGH
US$45.00
0
STRONG BUY
9
BUY
0
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 18/09/2026
Oculis Holding stock metrics
P/E
-4.53
P/B
1.77
EV/EBITDA
-4.66
RETURN ON EQUITY
-4.5%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
64.8%
FLOAT SHARES
37,032,915
AVG. DAILY VOLUME (30D)
257,420
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.3%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Oculis Holding stock
What does Oculis Holding do?
Oculis Holding AG is a company in the Healthcare sector, Biotechnology industry, headquartered in Switzerland.
The CEO is Riad Sherif, the company employs around 60 people.
The IPO was on 18/05/2021; the stock trades on NASDAQ under the ticker OCS.
What do analysts say about Oculis Holding stock?
9 analysts rate the stock, the consensus is Buy (as of 18/09/2026).
The average price target is US$36.75, ranging from US$26.00 to US$45.00, with a median of US$38.00.
This is an external assessment, not a statement by Market Jury.
When does Oculis Holding report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -23% stronger than usual.
Does Oculis Holding pay a dividend?
No, Oculis Holding currently does not pay a dividend.
Which stocks are comparable to Oculis Holding?
Comparable stocks include BeOne Medicines, Pharvaris, Idorsia, Basilea Pharmaceutica, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and argenx.
How can I get Oculis Holding stock analyzed?
Clicking "Analyze stock" lets five strategies assess Oculis Holding against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.